# S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

> **NCT03457337** · PHASE2 · UNKNOWN · sponsor: **Henan Cancer Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Advanced NSCLC With EGFR Mutation

## Interventions

- **DRUG:** S-1 plus Gefitinib
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT03457337
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03-28
- **Primary completion:** 2020-10-31
- **Final completion:** 2021-10-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03457337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03457337, "S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03457337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*